ClinicalTrials.gg

Program

silevertinib

Also written as “RVU120”, “silevertinib in combination with temozolomide” and “silevertinib (BDTX-1535) monotherapy”.

Its studies are mostly in Leukemia, Myeloid, Acute · Glioblastoma · Primary Myelofibrosis · Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 2, since Sep 7, 20217 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ryvu Therapeutics52 open or runningphase 2since Sep 7, 2021Sep 7, 2021Dec 2026phase 2 · NCT06987058
Black Diamond Therapeutics22 open or runningphase 2since Feb 15, 2022Feb 15, 2022Nov 2028phase 2 · NCT07326566

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2021First study: phase 2 study in RecurrenceNew to Ryvu TherapeuticsRyvu Therapeutics · NCT05052255 · 66 enrolled · Poland, Spain
  2. Feb 15, 2022Black Diamond Therapeutics's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Black Diamond TherapeuticsBlack Diamond Therapeutics · NCT05256290 · 200 enrolled · United States
  3. Dec 19, 2023Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06191263 · 98 planned · France, Italy, Poland and more
  4. Jan 5, 2024Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06268574 · 62 enrolled · France, Italy, Poland and more
  5. Apr 29, 2024Phase 2 study in Primary MyelofibrosisRyvu Therapeutics · NCT06397313 · 36 enrolled · Italy, Poland
  6. May 15, 2025Phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06987058 · 14 planned · France, Poland
  7. Jan 7, 2026Phase 2 study in GlioblastomaBlack Diamond Therapeutics · NCT07326566 · 162 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06987058
  2. Aug 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteRyvu Therapeutics · NCT06191263
  3. Nov 2028Primary completion: phase 2 study in GlioblastomaBlack Diamond Therapeutics · NCT07326566

TargetBeta

EGFR →read by rule
“An orally bioavailable, brain penetrating, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07326566Glioblastoma · United States2RecruitingBlack Diamond TherapeuticsNov 2028162
NCT06987058Leukemia, Myeloid, Acute · France, Poland2By invitationRyvu TherapeuticsDec 202614
NCT06397313Primary Myelofibrosis · Italy, Poland2TerminatedRyvu TherapeuticsJun 30, 202636
NCT06268574Leukemia, Myeloid, Acute · France, Italy, Poland and more2TerminatedRyvu TherapeuticsJun 30, 202562
NCT06191263Leukemia, Myeloid, Acute · France, Italy, Poland and more2RecruitingRyvu TherapeuticsAug 202798
NCT05256290Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingBlack Diamond TherapeuticsNov 3, 2025200
NCT05052255Recurrence · Poland, Spain2TerminatedRyvu TherapeuticsOct 2, 202566

How it is read

Names in the registry

  • “RVU120”, 5 entries
  • “silevertinib in combination with temozolomide”, 1 entry
  • “silevertinib (BDTX-1535) monotherapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.